Samrat Pharmachem Limited has announced that its Board of Directors will convene on May 30, 2026, to review and approve the company's audited financial results for the financial year ended March 31, 2026. The pharmaceutical chemicals manufacturer issued the notice on March 25, 2026, in compliance with regulatory requirements.

Board Meeting Details

The board meeting is scheduled to take place at the company's corporate office with specific timing and agenda items outlined for stakeholder information.

Meeting Agenda and Compliance

The primary agenda involves consideration and approval of audited standalone financial results prepared under Indian Accounting Standards (Ind-As) for FY26. The board will also review statutory auditor reports accompanying the financial statements. This notice has been issued pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting notice will be made available on the company's website at www.samratpharmachem.com as required under Regulation 46 of SEBI LODR regulations. Company Secretary and Compliance Officer Nishant Kankaria signed the official communication.

Post-Meeting Procedures

Following the board meeting conclusion, Samrat Pharmachem Limited will communicate the audited financial results to stock exchanges. The company has committed to making necessary announcements in the press and on its website as mandated under listing agreement requirements.

The pharmaceutical chemicals manufacturer operates from its registered office and factory located at GIDC Phase 4, Ankleswar, Gujarat, while maintaining its corporate office in Mumbai for administrative functions.

Samrat Pharmachem Limited has announced its standalone unaudited financial results for the quarter and nine months ended December 31, 2025, revealing a significant shift from profitability to losses compared to the previous year. The pharmaceutical chemicals manufacturer's performance reflects challenging market conditions during the reporting period.

Financial Performance Overview

The company's financial results show a marked deterioration in profitability metrics across both quarterly and nine-month periods. The most striking change is the transition from substantial profits in the previous year to significant losses in the current reporting period.

Nine-Month Performance Analysis

The nine-month results further highlight the company's challenging operational environment. While total income from operations showed marginal growth, the bottom line performance deteriorated significantly.

Quarterly Revenue Trends

The company's revenue performance showed mixed trends across quarters. Total income from operations in Q3 FY26 stood at Rs 6,382.71 lakhs, representing a marginal increase of 0.25% compared to Rs 6,366.53 lakhs in Q3 FY25. However, this was lower than the previous quarter (Q2 FY26) which recorded Rs 7,891.84 lakhs.

Tax Position and Capital Structure

Despite reporting losses, the company recorded a tax expense of Rs 16.80 lakhs for the nine-month period, compared to Rs 273.82 lakhs in the corresponding previous period. The paid-up equity share capital remained unchanged at Rs 308.97 lakhs with a face value of Rs 10 each share.

Regulatory Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2026, at the company's corporate office. The results have been published in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, appearing in both English and Gujarati newspapers.

The company operates in pharmaceutical chemicals manufacturing, which constitutes a single business segment. The figures for previous periods have been regrouped where necessary to conform to the current period's classification standards.